INLIGHT Phase 1 data continue to support WVE-007's novel mechanism of action to improve body composition by inducing fat loss without muscle loss, and support a once- or twice-yearly dosing regimen Six-month data from ongoing Phase 2a monotherapy trial in individuals with high BMI, high adiposity, and comorbidities anticipated in 2027 WVE-007/tirzepatide combination trial ongoing; Wave announces plan to integrate its maintenance clinical trial with this ongoing combination trial CAMBRIDGE, Mass., Nov. 13, 2 ...